查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301013

美國虛擬臨床試驗市場規模、份額和趨勢分析報告：按研究設計（干預、觀察、擴展訪問）、按適應症（癌症、心血管）、按階段、按地區、按細分市場、2023-2030 年趨勢

U.S. Virtual Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Indication (Oncology, Cardiovascular), By Phase, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國虛擬臨床試驗市場增長和趨勢

根據 Grand View Research, Inc. 的最新報告，到 2030 年，美國虛擬臨床試驗市場預計將達到 75.2 億美元。

從 2023 年到 2030 年，該市場預計將以 5.45% 的複合年增長率增長。 遠程醫療的採用、對患者多樣性的需求以及臨床試驗中數據收集的加強以及醫療保健數字化的不斷發展等因素是推動市場增長的因素。

在虛擬範式中，研究可以使用數字工具來加快招聘速度、減少管理費用並提高包容性。 例如，癌症中心開始使用人工智能 (AI) 將患者與臨床試驗相匹配。 這些平台從電子病歷的結構化和非結構化部分收集患者數據，確定資格，並將患者與 ClinicalTrials.gov 數據庫中適用的開放研究相匹配。 為此，我們使用自然語言處理和其他人工智能方法。

隨著監管機構努力應對先前嚴格的資格要求的擴大，這些尖端分析工具在癌症中的重要性正在迅速增長。 這一因素為美國虛擬臨床試驗市場提供了利潤豐厚的增長機會。 近年來，由於 COVID-19 大流行，遠程醫療的使用量激增。 這是因為大多數研究資助者都是以患者為中心的。

臨床試驗中患者入組和保留的最大障礙之一是患者的地理位置和社會經濟階層。 這也可以通過遠程醫療來解決，從而改善患者的多樣性。 這為人群中的特定疾病以及研究藥物對該人群的潛在影響提供了更真實的了解。 此外，在臨床研究中使用遠程醫療使患者不僅可以與研究人員更有效地互動，還可以與治療醫生更有效地互動。

疫情將研究從診所轉移到了家庭，迫使研究人員考慮新的數據收集方法。 FDA 已發布指令，暫時增加使用心電圖儀和肺活量計等用於遠程監測患者的非侵入性醫療設備的機會。 研究人員改變了評估頻率，尤其是在腫瘤學領域。 這些進展符合虛擬試驗方法，旨在衡量患者報告的結果並提高研究生成真實數據的能力。 受疫情影響，美國虛擬臨床試驗市場出現顯著增長。

美國虛擬臨床試驗市場報告亮點

  • 由於針對各種疾病的新藥開發進行的試驗數量激增，介入試驗設計領域將在 2022 年擁有最高的市場份額。
  • 擴大的准入領域潛力巨大，預計增長最快
  • 由於美國癌症患者數量增加，2022 年腫瘤領域將佔據市場份額 57.73%
  • 由於該領域越來越多地採用虛擬臨床試驗，中樞神經系統領域將出現最大的增長。
  • 由於許多研究目前處於 II 期試驗階段，因此 II 期臨床試驗部分在 2022 年佔據了最高的市場收入份額。
  • 隨著許多臨床試驗在德克薩斯州和佛羅裡達州等州進行，美國南部地區在美國市場佔據主導地位，2022年的銷售份額為33.25%。
  • 由於加利福尼亞州等專注於研究活動的州的存在，美國西部地區預計在預測期內增長最快。

內容

第一章調查方法及範圍

  • 市場細分和範圍
  • 市場定義
  • 信息獲取
    • 購買的數據庫
    • GVR 內部數據庫
    • 二手信息和第三方觀點
    • 初步調查
    • 初步調查的詳細信息
  • 信息分析
    • 數據分析模型
  • 市場形成和數據可視化
    • 產品流分析
  • 驗證和發布數據
  • 全球市場：計算複合年增長率
  • 輔助信息列表
  • 主要信息列表

第 2 章執行摘要

  • 市場概況
  • 分段快照
  • 衝突注意事項概覽

第三章市場變量、趨勢和範圍

  • 市場血統
    • 母公司市場分析
    • 補充市場分析
  • 美國虛擬臨床試驗市場 - 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 商業環境工具分析：美國虛擬臨床試驗市場
    • 波特五力分析
    • 杵分析
  • COVID-19 的影響分析

第 4 章美國虛擬臨床試驗市場：研究設計估算和趨勢分析

  • 按研究設計劃分的美國虛擬臨床試驗市場：主要要點
  • 美國虛擬臨床試驗市場：2022 年和 2030 年研究設計動態和市場份額分析
  • 介入治療
    • 2018-2030 年干預市場估計和預測（十億美元）
  • 觀察性的
    • 2018-2030 年觀察到的市場估算和預測（十億美元）
  • 擴展訪問權限
    • 2018-2030 年擴展接入市場估算和預測（十億美元）

第 5 章美國虛擬臨床試驗市場：適應症估計和估計/趨勢分析

  • 美國虛擬臨床試驗市場（按適應症）：主要要點
  • 美國虛擬臨床試驗市場：2022 年和 2030 年適應症趨勢和市場份額分析
  • 腫瘤學
    • 2018-2030 年腫瘤市場估計和預測（十億美元）
  • 心血管
    • 2018-2030 年心血管市場估計和預測（十億美元）
  • 消化系統疾病
    • 2018-2030 年胃腸病學市場估計和預測（十億美元）
  • 肌肉骨骼疾病
    • 2018-2030 年肌肉骨骼疾病市場估計和預測（十億美元）
  • 感染
    • 2018-2030 年傳染病市場估計和預測（十億美元）
  • 中樞神經系統
    • 2018-2030 年中樞神經系統市場估計和預測（十億美元）
  • 內分泌和代謝疾病
    • 2018-2030 年內分泌和代謝疾病市場估計和預測（十億美元）
  • 其他
    • 2018-2030 年其他指標市場估計和預測（十億美元）

第 6 章美國虛擬臨床試驗市場：階段評估和趨勢分析

  • 美國虛擬臨床試驗市場（按階段）：主要要點
  • 美國虛擬臨床試驗市場：2022 年和 2030 年階段轉變和市場份額分析
  • 第一階段
    • 2018-2030 年第一階段市場估算和預測（十億美元）
  • 第二階段
    • 2018-2030 年第二階段市場估算和預測（十億美元）
  • 第三階段
    • 2018-2030 年第三階段市場估算和預測（十億美元）
  • 第四階段
    • 2018-2030 年第四階段市場預估和預測（十億美元）

第 7 章：美國虛擬臨床試驗市場：區域分析

  • 2022 年和 2030 年美國虛擬臨床試驗區域市場份額分析
    • 東北
    • 中西部
    • 南
    • 西

第 8 章競爭格局

  • 公司分類
  • 戰略規劃
  • 公司簡介/列表
    • ICON, plc
    • Parexel International Corporation
    • IQVIA
    • Labcorp Drug Development
    • Medidata Solutions
    • Oracle
    • Signant Health
    • Medable, Inc.
    • Halo Health Systems
    • Science 37
Product Code: GVR-4-68040-085-3

U.S. Virtual Clinical Trials Market Growth & Trends

The U.S. virtual clinical trials market size is expected to reach USD 7.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.45% from 2023 to 2030. Factors such as the adoption of telehealth, the need for patient diversity clubbed with enhanced data collection in clinical trials, and the increasing digitalization in healthcare are factors driving the growth of the market.

In a virtual paradigm, researchers can use digital tools to speed up hiring, cut down on overheads, and increase inclusivity. For patient-trial matching, for instance, cancer centers are starting to use artificial intelligence (AI). These platforms collect patient data from both structured and unstructured parts of electronic medical records, determine eligibility, and match patients to pertinent open studies in the ClinicalTrials.gov database. They use natural language processing and other AI approaches for this purpose.

The importance of these cutting-edge analytics tools in cancer is rising rapidly, as regulators work to enlarge previously stringent eligibility requirements. This factor is representing lucrative growth opportunities for the virtual clinical trials market in the United States. As a result of the COVID-19 pandemic, telemedicine has seen a sharp increase in usage in recent years. This is because most of the sponsors funding research studies have placed a greater emphasis on patient-centricity.

One of the biggest obstacles to patient enrollment and retention in clinical trials is the patient's geographic location and/or socioeconomic class. This is addressed via telemedicine, which also improves the possibility of better patient diversity. This provides a more realistic picture of a certain illness in a population and the potential effects of an investigational drug on that population. Furthermore, patients can interact with researchers as well as the treating doctors more effectively, when telemedicine is used in clinical research.

The pandemic switched research attention from study clinics to homes, leading researchers to consider novel methods for data gathering. The FDA published instructions to temporarily increase access to noninvasive medical devices for remote patient monitoring, such as electrocardiographs and spirometers. Researchers have changed the assessment frequency specifically in oncology. These developments are compatible with the virtual trial approach, which aims to increase the ability of studies to gauge patient-reported outcomes and produce real-world data. The U.S. market for virtual clinical trials has observed notable growth due to the pandemic.

U.S. Virtual Clinical Trials Market Report Highlights

  • The interventional study design segment accounted for the highest market share in 2022 due to the rapid rise in the number of experiments being performed to develop novel medications for various diseases
  • The expanded access segment is anticipated to experience maximum growth as it represents great potential
  • The oncology segment dominated the market in 2022 with a revenue share of 57.73% owing to the rising cases of cancer in the United States
  • The CNS indication segment is expected to witness maximum growth due to the increasing adoption of virtual clinical trials in this area
  • The Phase II trials segment accounted for the highest revenue share in 2022 in the market due to many studies currently being under this study phase
  • The Southern region dominated the U.S. market in 2022 with a revenue share of 33.25%, owing to a significant number of clinical trials being carried out in states such as Texas and Florida
  • The Western region of the United States is anticipated to experience maximum growth during the forecast period, aided by the presence of states such as California that strongly focus on research activities

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1: Commodity flow approach
      • 1.5.1.2. Approach 2: Country wise market estimation using bottom-up approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. U.S. Virtual Clinical Trials Market - Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. The increasing healthcare digitization
      • 3.2.1.2. The need for patient diversity clubbed with enhanced data collection in clinical trials
      • 3.2.1.3. Adoption of telehealth
      • 3.2.1.4. Alliances between biotechnology, pharmaceutical & clinical research organization
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Data security
  • 3.3. Business Environmental Tools Analysis: U.S. Virtual Clinical Trials Market
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. U.S. Virtual Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 4.1. U.S. Virtual Clinical Trials Market, By Study Design: Key Takeaways
  • 4.2. U.S. Virtual Clinical Trials Market: Study Design Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Interventional
    • 4.3.1. Interventional Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Observational
    • 4.4.1. Observational Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Expanded access
    • 4.5.1. Expanded Access Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Virtual Clinical Trials Market: Indication Estimates & Trend Analysis

  • 5.1. U.S. Virtual Clinical Trials Market, By Indication: Key Takeaways
  • 5.2. U.S. Virtual Clinical Trials Market: Indication Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Oncology
    • 5.3.1. Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Cardiovascular
    • 5.4.1. Cardiovascular Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Digestive Diseases
    • 5.5.1. Digestive Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Musculoskeletal Diseases
    • 5.6.1. Musculoskeletal Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Infectious Diseases
    • 5.7.1. Infectious Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. CNS
    • 5.8.1. CNS Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Endocrinology & Metabolic Disease
    • 5.9.1. Endocrinology & Metabolic Disease Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Other Indications Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Virtual Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. U.S. Virtual Clinical Trials Market, By Phase: Key Takeaways
  • 6.2. U.S. Virtual Clinical Trials Market: Phase Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Phase I
    • 6.3.1. Phase I Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Phase II
    • 6.4.1. Phase II Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Phase III
    • 6.5.1. Phase III Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Phase IV
    • 6.6.1. Phase IV Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. U.S. Virtual Clinical Trials Market: Regional Analysis

  • 7.1. U.S. Virtual Clinical Trials Regional market share analysis, 2022 & 2030
    • 7.1.1. Northeast
      • 7.1.1.1. Northeast Market estimates and forecast, 2018 - 2030
    • 7.1.2. Midwest
      • 7.1.2.1. Midwest Market estimates and forecast, 2018 - 2030
    • 7.1.3. South
      • 7.1.3.1. South Market estimates and forecast, 2018 - 2030
    • 7.1.4. West
      • 7.1.4.1. West Market estimates and forecast, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. ICON, plc
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Parexel International Corporation
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. IQVIA
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Labcorp Drug Development
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Medidata Solutions
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Oracle
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Signant Health
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Medable, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Halo Health Systems
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Science 37
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Virtual Clinical Trials market, by study design, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Virtual Clinical Trials market, by indication, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Virtual Clinical Trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Virtual Clinical Trials market, by region, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 U.S. virtual clinical trials market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value - chain - based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 U.S. Virtual Clinical Trials - Industry value chain analysis
  • Fig. 15 U.S. virtual clinical trials market driver analysis
  • Fig. 16 U.S. virtual clinical trials market restraint analysis
  • Fig. 17 U.S. virtual clinical trials market: Porter's Five Forces analysis
  • Fig. 18 U.S. virtual clinical trials market: PESTLE analysis
  • Fig. 19 U.S. virtual clinical trials market: Study design outlook and key takeaways
  • Fig. 20 U.S. virtual clinical trials market: Study design market share analysis, 2022 & 2030
  • Fig. 21 U.S. interventional study market, 2018 - 2030 (USD Billion)
  • Fig. 22 U.S. observational study market, 2018 - 2030 (USD Billion)
  • Fig. 23 U.S. expanded access study market, 2018 - 2030 (USD Billion)
  • Fig. 24 U.S. virtual clinical trials market: Indication outlook and key takeaways
  • Fig. 25 U.S. virtual clinical trials market: Indication market share analysis, 2022 & 2030
  • Fig. 26 U.S. oncology market, 2018 - 2030 (USD Billion)
  • Fig. 27 U.S. cardiovascular market, 2018 - 2030 (USD Billion)
  • Fig. 28 U.S. digestive diseases market, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. musculoskeletal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 30 U.S. infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig. 31 U.S. CNS market, 2018 - 2030 (USD Billion)
  • Fig. 32 U.S. endocrinology and metabolic diseases market, 2018 - 2030 (USD Billion)
  • Fig. 33 U.S. other indications market, 2018 - 2030 (USD Billion)
  • Fig. 34 U.S. virtual clinical trials market: Phase outlook and key takeaways
  • Fig. 35 U.S. virtual clinical trials market: Phase market share analysis, 2022 & 2030
  • Fig. 36 U.S. phase I virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 37 U.S. phase II virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 38 U.S. phase III virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 39 U.S. phase IV virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 40 Regional marketplace: Key takeaways
  • Fig. 41 Northeast U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Midwest U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 South U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 West U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 45 Key company categorization
  • Fig. 46 Company market positioning
  • Fig. 47 Market participant categorization
  • Fig. 48 Strategy framework